Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TXG 10x Genomics
48.320+0.860+1.81%
Close
02/07 16:00 ET
High
48.490
Open
47.320
Turnover
30.89M
Low
46.440
Pre Close
47.460
Volume
651.04K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
Ultima Genomics Announces Collaboration With 10x Genomics to Enable Seamless Integration of Chromium Single Cell Applications on Ultima Sequencers
NEWARK, Calif., Feb. 6, 2023 /PRNewswire/ -- Ultima Genomics, Inc. and 10x Genomics today announced a collaboration to integrate use of the 10x Genomics Chromium Single Cell Gene Expression solution
Rockefeller Capital Management L.P. Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG)
Rockefeller Capital Management L.P. increased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 95.2% during the third quarter, according to its most recent filing with the S
UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group started coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report released on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price tar
10x Genomics (NASDAQ:TXG) Now Covered by Analysts at UBS Group
UBS Group assumed coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report report published on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 p
10x Genomics Initiated at Neutral by UBS
10x Genomics Price Target Announced at $50.00/Share by UBS
The Past Three Years for 10x Genomics (NASDAQ:TXG) Investors Has Not Been Profitable
It is a pleasure to report that the 10x Genomics, Inc. (NASDAQ:TXG) is up 49% in the last quarter. But that doesn't change the fact that the returns over the last three years have been less than pl
UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50
UBS analyst John Sourbeer initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces Price Target of $50.
10x Genomics Initiated With a Neutral at UBS
Company Overview
More
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
CEO： Dr. Serge Saxonov, PhD
Market： NASDAQ
Listing Date： 09/12/2019
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet